



Translation

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Alfresa Holdings Corporation
June 23, 2026

**Notice Regarding the Capital and Business Alliance
Between Alfresa Corporation and eMind, Inc.
Aimed at Helping Improve the Quality of Healthcare and Patients' Quality of Life**

Subsidiary Alfresa Corporation (head office: Chiyoda-ku, Tokyo; representative director & president: Yusuke Fukujin; hereinafter “Alfresa”) a company engaged in the Ethical Pharmaceuticals Wholesaling Business, has concluded an investment agreement and a basic agreement regarding a business alliance with eMind, Inc. (head office: Chiyoda-ku, Tokyo; Chief Executive Officer: David Liebreich; hereinafter “eMind”), a company that collects data via smartphones and wearable devices and conducts research and development on, provides services related to, and operates AI-based prediction systems for disease onset in addition to other tools. The details of these agreements are as follows.

1. Background and Purpose of the Alliance

The Alfresa Group has adopted the solutions business as a growth area under 25–27 Mid-term Management Plan Vision 2032 Stage 2: Pioneering the Future with Our Collective Strength.*¹ In the Ethical Pharmaceuticals Wholesaling Business, the Group is developing and deploying various products and services*² aimed at enhancing convenience for patients and medical institutions through health technology and at providing solutions for pharmaceutical companies.

Meanwhile, under its mission “of contributing to society by supporting people’s mental and physical health,” eMind is advancing the development of digital health services that support patients with mental illnesses, neurological disorders, migraines, and ALS (amyotrophic lateral sclerosis). These services include tools that combine AI with behavioral and lifestyle data collected from patients’ smartphones and other devices to promote disease awareness and provide recommendations to undergo medical examinations, apps that support patient health, and medical examination support systems. The company is also considering expansion into digital therapeutics.*³ Furthermore, through joint research*⁴ with universities and pharmaceutical companies, eMind is working to verify the clinical validity of the technologies above.

Through this alliance, Alfresa will leverage its network of medical institutions and pharmaceutical companies as a pharmaceutical wholesaler to collaborate with eMind on the commercialization of digital health services utilizing the digital technologies developed and offered by the latter company and on said services' introduction into healthcare settings. Furthermore, both companies will jointly promote the practical social implementation of solutions that contribute to the advancement of healthcare and will work to help improve the quality of healthcare and patients' quality of life.

*1 Reference: Notice Regarding the Formulation of the 25–27 Mid-term Management Plan Vision 2032 Stage 2: Pioneering the Future with Our Collective Strength (published on May 15, 2025 on the Alfresa Holdings Corporation corporate website)

https://ssl4.eir-parts.net/doc/2784/fr_material17/250645/00.pdf

*2 Products and services: System tools that are planned, developed, and provided by the Alfresa Group to help solve issues for stakeholders

*3 Digital therapeutics: Medical software and other tools developed to treat, diagnose, and manage diseases using digital technology

*4 Reference:

eMind, Tohoku University, and Otsuka Pharmaceutical Launch Epilepsy Smart Medical Joint Research Project (Phase II) Aiming to Start and Expand Epilepsy Treatment Support System (published on July 3, 2025)

<https://emind.jp/wp-content/uploads/2025/07/eMind-Tohoku-University-and-Otsuka-Pharmaceutical-Launch-Epilepsy-Smart-Medical-Joint-Research-Project-Phase-II-Aiming-to-Start-and-Expand-Epilepsy-Treatment-Support-System.pdf>

eMind and St. Marianna University School of Medicine Enter into a Comprehensive Partnership Agreement to Accelerate Next-Generation Medical Innovation in SaMD and Non-SaMD Fields Through Proprietary AI Technology (published on April 28, 2026)

<https://prtimes.jp/main/html/rd/p/000000013.000111093.html> (Japanese only)

2. Outline of the Capital and Business Alliance

(1) Summary of the Investment Agreement

- 1) Total investment amount: Approximately ¥350 million
- 2) Use of funds: Expenses related to the research and development of digital therapeutics, digital health services, and other activities

(2) Summary of the Basic Agreement Regarding the Business Alliance

1) The two companies will examine the potential for deploying digital health services for medical use that target migraines and ALS in pharmaceutical companies and other settings.

2) Alfresa will leverage its network of medical institutions and pharmaceutical manufacturers to support the introduction and use of digital health services developed and offered by eMind.

3) The two companies will examine the potential for joint development and commercialization of new digital therapeutics and digital health services.

3. Overview of eMind, Inc. (as of May 31, 2026)

(1) Corporate name	eMind, Inc.	
(2) Head office	1-11-1 Marunouchi, Chiyoda-ku, Tokyo	
(3) Name and title of representative	David Liebreich, Chief Executive Officer	
(4) Description of business	<ul style="list-style-type: none"> • Information provision service operations • Provision of information system services • Planning, design, and management of information systems • Design, development, sale, and maintenance of computer software • Marketing research and consulting services related to information systems • Management consulting services 	
(5) Paid-in capital	¥106 million	
(6) Date of founding	July 28, 2020	
(7) Relationship between Alfresa Holdings Corporation, Alfresa Corporation, and eMind, Inc.	Capital relationship	None
	Human relationship	None
	Transactional relationship	None
	Related parties	None

4. Timeline

Conclusion of capital and business alliance: June 12, 2026

5. Outlook

Although the impact of these agreements on its business performance for the fiscal year ending March 31, 2027 is expected to be minor, the Alfresa Group believes that the agreements will help enhance the Group's corporate value over the medium to long term. Going forward, if any matters concerning these agreements that require disclosure arise, the Group will promptly issue announcements.

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, operating dispensing pharmacies, regenerative medicine-related business, and CRO business. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥3.1 trillion for the fiscal year ended March 31, 2026. For more information, please see: <https://www.alfresa.com/eng/>